Molecular mechanism and treatment of pulmonary fibrosis
10.12092/j.issn.1009-2501.2022.10.008
- Author:
Shiqin ZHOU
1
;
Yali LUO
1
;
Wen ZHOU
1
;
Xiaofeng QI
1
;
Mengyong XIAO
1
;
Yali LUO
2
Author Information
1. Provincial Key Laboratory of Molecular Medicine and TCM Prevention and Treatment of Major Diseases in Colleges, Universities of Gansu Province, Gansu University of Traditional Chinese Medicine
2. Department of Pathology, College of Basic Medicine
- Publication Type:Journal Article
- Keywords:
epithelial cells;
epithelial-mesenchymal transition (EMT);
fibroblasts;
macrophages;
mitochondrion;
pulmonary fibrosis;
telomere;
treatment status
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(10):1133-1147
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary fibrosis (PF) is a chronic progressive interstitial lung disease. The pathogenesis of PF is not yet clear. The two anti fibrosis drugs approved for IPF treatment, nidanib and pirfenidone, have been proved to reduce the decline of pulmonary function of pF, but both have side effects. So far, there is no obvious and effective treatment to prevent the progress of pF. Therefore, this review focuses on the different cells, molecular mechanisms involved in PF and the current treatment progress of PF, so as to provide theoretical support for a better understanding of these cells, molecular mechanisms and drug development and application in PF.
